Select Acadia Healthcare Hospitals to Participate in Clinical Trial for Acute Suicidal Ideation and Behavior in Major Depression Drug
September 14 2022 - 8:00AM
Business Wire
Program aligns with Acadia’s mission to provide
safe, innovative care to patients in great need
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced
that select facilities from its network of acute care behavioral
health hospitals will participate in a registration directed trial
to study participants with suicidal ideation and behavior with
major depression. This study is sponsored by Seelos Therapeutics
(NASDAQ: SEEL) for its SLS-002 investigational drug. Acadia
hospitals that meet the criteria for participation as clinical
trial sites will be able to offer enrollment in this study to
eligible patients who exhibit specific symptoms and meet the
enrollment conditions.
“We are pleased that select hospitals from our network will take
part in this program given its rigorous and comprehensive
requirements,” said Dr. Michael Genovese, M.D., Chief Medical
Officer of Acadia Healthcare. “Our acute care behavioral health
hospitals strive to provide quality care and innovative treatments.
SLS-002 has shown promise in Part 1 of this trial, and we are
hopeful that it can enhance the positive patient outcomes for these
at-risk groups.”
SLS-002 is intranasal racemic ketamine with two investigational
new drug applications for the treatment of acute suicidal ideation
and behavior in patients with major depression. Seelos looks to
address an unmet need to treat these conditions in the U.S. with
SLS-002. The protocol requires a five-dose regimen spread over the
first 15 days of treatment (both in-and out-patient) after medical
assessment. This is Part 2 of the study, which is randomized,
double-blind, and placebo controlled. The purpose of the study is
to evaluate the efficacy, safety, and tolerability of repeat doses
of SLS-002 in the target indication.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases.
About Acadia Healthcare Acadia is a leading provider of
behavioral healthcare services across the United States. As of June
30, 2022, Acadia operated a network of 239 behavioral healthcare
facilities with approximately 10,600 beds in 39 states and Puerto
Rico. With more than 22,500 employees serving approximately 70,000
patients daily, Acadia is the largest stand-alone behavioral health
company in the U.S. Acadia provides behavioral healthcare services
to its patients in a variety of settings, including inpatient
psychiatric hospitals, specialty treatment facilities, residential
treatment centers and outpatient clinics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005203/en/
Gretchen Hommrich Vice President, Investor Relations (615)
861-6000
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acadia Healthcare (NASDAQ:ACHC)
Historical Stock Chart
From Jul 2023 to Jul 2024